Stockscreener 앱 받기
20.74
1.61%
-0.34
시간 외 거래:
20.74
전일 마감가:
$21.08
열려 있는:
$21.14
하루 거래량:
357.76K
Relative Volume:
0.39
시가총액:
$1.31B
수익:
-
순이익/손실:
$-100.44M
주가수익비율:
-9.3423
EPS:
-2.22
순현금흐름:
$-105.32M
1주 성능:
-6.15%
1개월 성능:
-4.69%
6개월 성능:
-23.53%
1년 성능:
-47.19%
1일 변동 폭
$20.64
$21.25
1주일 범위
$20.64
$23.67
52주 변동 폭
$13.22
$47.48
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
명칭
Structure Therapeutics Inc Adr
전화
(628) 229-9277
주소
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
GPCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
20.74 | 1.31B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-02 | 개시 | Citigroup | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-12-04 | 개시 | H.C. Wainwright | Buy |
| 2024-09-23 | 개시 | Morgan Stanley | Overweight |
| 2024-05-21 | 개시 | JP Morgan | Overweight |
| 2024-04-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2023-07-27 | 개시 | Piper Sandler | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2023-02-28 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | Guggenheim | Buy |
| 2023-02-28 | 개시 | Jefferies | Buy |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
Data-Based Insights About Structure Therapeutics Inc ADR (GPCR) - Stocksregister
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
Cantor Fitzgerald Comments on GPCR FY2026 Earnings - Defense World
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarketsNORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA
Cantor Fitzgerald Estimates GPCR FY2025 Earnings - Defense World
Oral Proteins and Peptides Market Report Latest Trends and Future Opportunities Analysis - openPR.com
Structure Therapeutics Inc. (NASDAQ:GPCR) Given Average Recommendation of “Buy” by Brokerages - Defense World
Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating - TipRanks
Bank of America Corp DE Has $1.47 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
GLP-1 Receptor Agonists: The Surge of M&A Activity and the Future of Metabolic Health - The National Law Review
Structure Therapeutics Set for Jefferies and Goldman Sachs Healthcare Conference Presentations in June - Stock Titan
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints - standard-journal.com
BNP Paribas Financial Markets Increases Stake in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
BNP Paribas Financial Markets Makes New $304,000 Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX) - The Globe and Mail
Structure Therapeutics’ SWOT analysis: oral obesity drug stock poised for growth - Investing.com
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $78.00 - Defense World
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail
Structure Therapeutics (NASDAQ:GPCR) Price Target Lowered to $75.00 at HC Wainwright - Defense World
FY2025 Earnings Forecast for GPCR Issued By Leerink Partnrs - Defense World
Envestnet Asset Management Inc. Has $201,000 Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Tower Research Capital LLC TRC Acquires 3,549 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - The AM Reporter
Structure Therapeutics Reports Increased Losses Amid Rising R&D Costs - TipRanks
Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights - Stock Titan
Wells Fargo & Company MN Boosts Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Analyzing Ratios: Structure Therapeutics Inc ADR (GPCR)’s Financial Story Unveiled - DWinneX
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), AnaptysBio (ANAB) and Alignment Healthcare (ALHC) - The Globe and Mail
Structure Therapeutics Inc ADR (NASDAQ: GPCR) Is Up 1.57% So Far This Year: What Will Happen Next? - Stocksregister
Structure Therapeutics (NASDAQ:GPCR) Research Coverage Started at Citigroup - Defense World
Structure Therapeutics Inc ADR (GPCR) expanding its growth trajectory ahead - Sete News
Buy Recommendation for Structure Therapeutics: Promising Pipeline and Obesity Treatment Market Potential - TipRanks
Citi sets Structure Therapeutics stock Buy rating, $60 target By Investing.com - Investing.com India
Technical analysis of Stoke Therapeutics Inc (STOK) stock chart patterns - uspostnews.com
Terns Pharmaceuticals Inc (TERN) deserves deeper analysis - uspostnews.com
A stock that deserves closer examination: Structure Therapeutics Inc ADR (GPCR) - uspostnews.com
What is the investor’s view on LSB Industries, Inc (LXU)? - uspostnews.com
Geode Capital Management LLC Increases Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Pfizer eyes smaller drugmakers after failure of obesity pill - medwatch.com
The Potential Rise in the Price of Structure Therapeutics Inc ADR (GPCR) following insiders activity - knoxdaily.com
A Guide To The Risks Of Investing In Jamf Holding Corp (JAMF) - knoxdaily.com
GPCR Stock: A Voyage Through Structure Therapeutics Inc ADR’s Finances - investchronicle.com
Recent Insider Activity Could Benefit Pacific Premier Bancorp, Inc (PPBI) - knoxdaily.com
Barclays PLC Increases Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
24,530 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by Mariner LLC - Defense World
Market Update: CytomX Therapeutics Inc (CTMX) Sees Negative Movement, Closing at 0.71 - DWinneX
Stock Market Recap: Barrick Gold Corp (GOLD) Concludes at 19.30, a 1.31 Surge/Decline - DWinneX
Market Resilience: ReShape Lifesciences Inc (RSLS) Finishes Weak at 0.36, Down -0.85 - DWinneX
Gaining Ground: Structure Therapeutics Inc ADR (GPCR) Closes Lower at 23.62, Down -0.51 - DWinneX
JPMorgan Chase & Co. Has $876,000 Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Acquired by LPL Financial LLC - Defense World
LPL Financial LLC Has $341,000 Stock Holdings in AdvisorShares Dorsey Wright FSM All Cap World ETF (NASDAQ:DWAW) - American Banking and Market News
Structure Therapeutics Inc Adr (GPCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
0.23%
자본화:
|
볼륨(24시간):